Outer Biosciences utilizes living skin tissue and AI to innovate skincare research. Here's how Michal Polansky bridges science and beauty.
In a world where AI is entwined with every facet of life, one startup is uniting technology and biology in a transformative way. Outer Biosciences, founded by Michael Polansky, is pushing the boundaries of skincare research by leveraging living human tissue kept alive outside the body. This innovative approach aims to uncover new skincare compounds that can significantly benefit dermatology while addressing the limitations of traditional testing methods.
Michael Polansky may be known as Lady Gaga's partner and a former deputy to Sean Parker, but his venture into the intersection of AI and biology is garnering attention in its own right. Raised in Minnesota, Polansky graduated from Harvard with degrees in applied mathematics and intelligence/">computer science. He spent three years at the hedge fund Bridgewater Associates before making the leap to Silicon Valley.
Through a unique connection back home, Polansky found himself at Founders Fund, where he worked alongside industry giants such as Peter Thiel and Sean Parker. This relationship with Parker paved the way for Polansky's future, as Parker's family office became a pivotal part of his career until his life took a turn with the COVID-19 pandemic and meeting Lady Gaga.
Founded in 2022, Outer Biosciences tackles a significant challenge in the beauty industry: the slow pace of innovation in biology and chemistry compared to software. Traditional methods often rely on animal testing or lab-grown organoids, which fail to replicate the intricacies of human tissue. The company’s solution involves sourcing living human skin tissue from surgeries, primarily plastic surgeries, through ethical means.
Polansky emphasizes Outer Biosciences' commitment to ethical practices by noting that the company collaborates with established biobanks and non-profit organizations that ensure donor privacy and consent. They maintain a rigorous protocol to transport tissue samples immediately after surgeries, preserving their viability for extended periods.
Outer Biosciences has developed a proprietary support system that nourishes this living tissue, allowing them to keep it alive for up to 30 days. This extension of life allows researchers to observe biological processes, such as collagen remodeling, that unfold over weeks.
At the core of Outer Biosciences' research is an AI model that predicts which untested chemicals could have a positive impact on skin functions. The synergy between living tissue and artificial intelligence marks a significant evolution in skincare development. Chemically active substances undergo rigorous testing in the lab-grown tissue environment, and results are fed back into the AI, refining its predictive capabilities.
This data-driven methodology has clearly accelerated the pace of discovering potential skin-active ingredients. Initially, the process relied solely on mining scientific literature and forming partnerships with research institutions, resulting in modest outputs. With AI integrated into the operations, Outer Biosciences now generates a new potential ingredient approximately every six weeks, significantly increasing its chances of discovery.
Polansky notes that the overall universe of skin-active ingredients is relatively small, estimated at roughly 200, which includes both FDA-approved and research-backed compounds. Instead of obtaining FDA approval for drugs, Outer Biosciences focuses on developing cosmetic ingredients, following a streamlined process that emphasizes safety testing under OECD guidelines.
Rather than create a consumer brand themselves, Outer Biosciences intends to license its skincare ingredients to established beauty and pharmaceutical companies. This strategic move allows the startup to leverage existing branding and distribution channels to bring its innovations to market more effectively.
Currently, four of the six active leads in Outer Biosciences’ pipeline appear promising for commercialization. The company also engages in collaborative research partnerships with various pharmaceutical firms that seek to understand the dermatological side effects of certain cancer treatments.
Despite attracting significant attention, Polansky has maintained a somewhat low profile, previously opting for silence on the company’s progress. Now, fueled by accumulating data and confidence in their research, he indicates a desire to work more publicly and promote the exciting work being done at Outer Biosciences.
While Outer Biosciences has carved out a unique niche by using living human tissue combined with advanced AI, it is not alone in this endeavor. Competitors like Vivodyne are also exploring lab-grown human organ tissues paired with AI for drug testing alternatives. Such advancements are shifting the paradigms of preclinical testing.
However, Polansky maintains confidence in Outer Biosciences' approach and proprietary data. The company generates information that isn’t readily available elsewhere, potentially positioning itself defensively against competition. It also benefits from reduced operational costs as its AI works efficiently on-site rather than through expansive cloud computing.
As Outer Biosciences continues to grow, Polansky is focused on developing a precise predictive model capable of identifying potential skin compounds without extensive prior testing. This ambitious goal aims to accelerate dermatological discovery to unprecedented levels.
The next steps for the company involve building a product-development team, guided by experienced individuals who can scale their promising compounds into real world products. Through this path, Polansky envisions Outer Biosciences not merely as a research entity, but as a transformative industry leader in the skincare space.
For now, the synergy between Paulansky's journey in life sciences, Lady Gaga's involvement in beauty and their dedication to innovative research signals that Outer Biosciences is set to redefine boundaries in skincare. As exciting discoveries continue to emerge, the world may soon witness a new era in skincare, powered by AI and living tissue.
When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.
Outer Biosciences has the potential to merge health and beauty into an entirely new market concept, and the work they are doing is just beginning to scratch the surface of what is possible.
For information on upcoming events in the tech and AI space, be sure to keep an eye out for gatherings and conferences in San Francisco, where innovation frequently thrives.